Company:  SEATTLE GENETICS INC /WA (SGEN)
Form Type:  4
Filing Date:  7/11/2018 
CIK:  0001060736 
Address:  21823 30TH DRIVE SE
SUITE
 
City, State, Zip:  BOTHELL, Washington 98021 
Telephone:  (425) 527-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$78.53  
Change: 
0.77 (0.99%)  
Trade Time: 
Sep 24  
Market Cap: 
$12.47B
Trade SGEN now with 

© 2018  
Description of Business
Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Our marketed product ADCETRIS®, or brentuximab vedotin, is approved by the United States Food and Drug Administration, or FDA, and the European Commission for four indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. ADCETRIS is commercially available in 70 countries, including in the United States, Canada, members of the European Union and Japan. We are collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES